explore -WSS

explore

author：leisure time 2025-09-27 09:44:33 - browse：31835

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Search called off for baby washed away in Pennsylvania flash flood

hotspot

WSS

Amazon on where the company's health care bets are headed next

Senate panel puts off hardest PBM reforms for another day

Biogen says it will cut costs by $700 million, slash 1,000 jobs

'Make People Better': The CRISPR babies story you probably don't know

Covid hospitalizations on the rise, Humana says

Medicaid rebukes states for mistakenly disenrolling children

focus

explore

leisure time

Medical records are filled with copy

What American doctors can learn from their Israeli counterparts

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Medical records are filled with copy

UHS says company favors patients whose insurance pays more

How one medical school became remarkably diverse

The 10 drugs up first for Medicare price negotiation

How to save PrEP access — and even expand it

House transparency, PBM reform bill gains bipartisan support

knowledge

Illumina names Agilent executive as new CEO

Roche’s Alnylam deal shows drug firms interested in heart drugs

In the gardens at Boston Children's Hospital, families find sanctuary

How to protect patients from sexual assault

Rise in cancer among younger people worries and puzzles doctors

How to protect patients from sexual assault

Wikipedia

hotspot

entertainment

explore